Medical oncologist Steven M. Horwitz discusses the development and impact of three new, widely used therapies for T cell lymphoma: pralatrexate, romidepsin, and brentuximab vedotin.
-
For Adult Patients
-
For Child & Teen Patients
-
For Healthcare Professionals
- Fellowships
- Residencies
- Medical Student Opportunities
- Continuing Medical Education
- Integrative Medicine Education Programs
- Continuing Nursing Education
- Survivorship Resources
- International Healthcare Professionals
- School of Radiation Therapy
- Cytotechnology Training
- Clinical Translational Research Training Program
- Comskil: Communication Skills Training Program & Research Laboratory
-
For Research Scientists
- More
- Languages